FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, randomized, phase III trial. Patients will be stratified
after breast surgery, as per investigational site; menopausal status; node negative
diagnosis, as per sentinel-node technique versus lymphadenectomy; hormone receptor status
(positive versus negative).